+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Monofocal IOLs, Multifocal / Trifocal IOLs), By Application (Private Hospitals, Public Hospitals, Ambulatory Surgery Centers, Ophthalmology Clinics), By End User (Elderly Population, Working-age Adults, Pediatric Patients), By Material (Hydrophobic Acrylic, Hydrophilic Acrylic, Silicone, Other Materials), By Folding & Delivery Method (Pre-loaded IOLs, Manually Loaded IOLs, Injectable IOL Systems), and Regional Forecast, 2026-2034
The global Foldable Intraocular Lenses (IOLs) market was valued at USD 4.80 billion in 2025 and is estimated at USD 5.10 billion in 2026. The market is projected to reach USD 8.23 billion by 2034, exhibiting an endpoint-consistent 6.2% CAGR during 2026–2034.
Foldable intraocular lenses are artificial lenses implanted to replace the natural crystalline lens, most commonly during cataract surgery. Foldable materials allow the optic and haptics to be inserted through a small corneal incision using an injector system and then unfold inside the capsular bag. This reduces incision size compared with rigid PMMA-style lenses and supports modern phacoemulsification, faster rehabilitation and lower surgically induced astigmatism.
The commercial market spans monofocal, multifocal/trifocal, toric and extended-depth-of-focus lenses produced primarily from hydrophobic acrylic, hydrophilic acrylic and silicone materials. Monofocal lenses remain the foundational high-volume option, while premium lenses increase market value by addressing presbyopia, intermediate vision and corneal astigmatism. Current premium portfolios from Alcon and Johnson & Johnson illustrate how refractive cataract surgery is shifting purchasing decisions from simple lens replacement toward customized visual outcomes.
Global procedure need remains substantial. WHO reported in February 2026 that cataract affects more than 94 million people worldwide and that nearly half of people experiencing cataract-related blindness still need access to surgery. This treatment gap, combined with population aging and expansion of surgical capacity in Asia-Pacific, creates a large long-term unit opportunity even as premium lens adoption lifts average selling value in North America, Europe and advanced Asian markets.
The study covers foldable pseudophakic intraocular lenses used during cataract surgery and refractive lens exchange, with the original source segmentation expanded into material, optical design and delivery system dimensions.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Monofocal IOLs; Multifocal / Trifocal IOLs |
| By Application | Public Hospitals; Private Hospitals; Ambulatory Surgery Centers; Ophthalmology Clinics |
| By End User | Elderly Population; Working-age Adults; Pediatric Patients |
| By Material | Hydrophobic Acrylic; Hydrophilic Acrylic; Silicone; Other Specialty Materials |
| By Folding / Delivery Method | Pre-loaded IOLs; Manually Loaded IOLs; Injectable IOL Systems |
| By Optical Design | Monofocal; Toric; EDOF / Enhanced Monofocal; Multifocal / Trifocal |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Alcon; Bausch + Lomb; ZEISS Medical Technology; Johnson & Johnson Surgical Vision; HOYA Surgical Optics; OPHTEC; STAAR Surgical; Lenstec; HumanOptics; Biotech Healthcare; Omni Lens Pvt. Ltd.; EyeOL UK; Eyebright Medical Technology; Wuxi Vision Pro; Haohai Biological Technology; Aurolab |
Cataract remains one of the most common causes of vision impairment and blindness. Each cataract extraction generally requires implantation of an IOL unless a specific clinical reason prevents implantation, directly linking surgical access to lens demand.
Age-related cataract is strongly associated with population aging. The growing number of older adults in North America, Europe, China, Japan and other markets supports sustained procedure growth and higher demand for lenses tailored to active post-retirement lifestyles.
Toric, EDOF and multifocal/trifocal lenses can reduce dependence on spectacles for selected patients. These lenses carry higher prices than standard monofocal IOLs and therefore contribute disproportionately to market value.
Basic cataract surgery and standard monofocal lenses may be publicly or privately reimbursed, while the incremental cost of presbyopia-correcting or advanced toric lenses is often paid by patients. Out-of-pocket affordability therefore strongly affects premium mix.
FDA classifies intraocular lenses as Class III implants under 21 CFR 886.3600. Manufacturers must maintain PMA approvals and supplements for design, manufacturing and labeling changes, increasing time and cost for product development.
Alcon launched Clareon TruPlus in the United States in April 2026 as an enhanced-design monofocal and toric IOL intended to increase depth of focus while preserving monofocal-quality distance vision. This category targets patients seeking more intermediate function without full multifocal optics.
Johnson & Johnson received U.S. FDA approval for TECNIS PureSee in March 2026 and expanded U.S. availability in June. EDOF products are positioned between monofocal and multifocal designs by extending range of vision while seeking to control halos and glare.
Bausch + Lomb launched the EyeGility preloaded IOL delivery system in the United States in July 2026 for the enVista family. One-handed operation and factory loading can reduce manual preparation and lens handling.
Toric IOLs correct pre-existing corneal astigmatism at the time of cataract surgery. As biometry and digital planning improve, more surgeons can offer astigmatism correction within routine cataract workflows.
WHO's 2026 cataract access warning highlights a large unmet surgery need. Expansion of affordable phacoemulsification and high-volume surgery in India, China and other emerging markets can drive substantial unit growth, even when standard monofocal lenses dominate.
Foldable IOL platforms are differentiated by material behavior, optical design, edge geometry, haptics, injector compatibility and the degree of spectacle independence they are intended to provide.
| Technology / Design | Clinical Objective | Market Relevance |
|---|---|---|
| Standard monofocal | Optimizes vision at one focal distance, usually distance. | Largest installed design because of affordability and predictable optical quality. |
| Toric monofocal | Corrects corneal astigmatism while restoring aphakic focusing power. | Premium segment with growing use as digital alignment improves. |
| Enhanced monofocal | Adds modest intermediate range while preserving monofocal-like distance performance. | Fast-growing middle tier between standard monofocal and EDOF. |
| EDOF | Extends the focal range to improve intermediate and functional near vision. | Premium growth segment focused on reduced spectacle dependence with controlled dysphotopsia. |
| Multifocal / trifocal | Creates multiple focal points for distance, intermediate and near vision. | High-value segment with greater potential for halos and glare in some patients. |
| Light-adjustable / post-implant adjustable | Allows optical power to be modified after surgery. | Advanced niche emphasizing personalized refractive outcomes. |
Monofocal IOLs remain the foundational high-volume category, while Multifocal / Trifocal IOLs deliver stronger value growth because of premium pricing and patient demand for spectacle independence.
Monofocal lenses offer predictable distance correction, broad surgeon familiarity and lower patient cost. Enhanced monofocal designs are extending this segment into premium intermediate-vision territory.
These designs divide incoming light across multiple focal distances and can reduce dependence on spectacles. Premium pricing and lifestyle demand support revenue growth, but patient selection is important because of halos and glare.
Private Hospitals are the leading value segment because they combine high cataract surgery volumes with greater adoption of premium toric, EDOF and multifocal lenses.
Private hospitals can invest in premium biometry, phacoemulsification and advanced lenses and often serve patients willing to pay additional out-of-pocket cost for refractive upgrades.
Public systems perform substantial cataract volume and are central to eliminating blindness backlogs. Standard monofocal foldable lenses dominate where reimbursement and procurement prioritize cost.
Cataract surgery is well suited to same-day care. ASCs emphasize predictable workflow, preloaded injectors and rapid room turnover.
Dedicated eye hospitals and clinics combine specialist surgeons, premium counseling and high procedural throughput, especially in mature private markets.
The Elderly Population represents the dominant patient group because age-related cataract remains the main indication for lens implantation.
Older adults account for the majority of cataract surgery and therefore drive the core monofocal and premium IOL market.
Younger patients with cataract or those undergoing refractive lens exchange are more likely to value spectacle independence and may select toric, EDOF or multifocal lenses.
Congenital cataract surgery is much smaller in volume and requires careful age, ocular-growth and amblyopia considerations, but remains clinically important.
Hydrophobic Acrylic is the leading material across modern foldable IOL portfolios because of optical stability and broad compatibility with small-incision injector systems.
Hydrophobic acrylic is widely used in premium and standard IOLs from Alcon, Johnson & Johnson and other leading companies. Low water content, controlled unfolding and established manufacturing support its leadership.
Hydrophilic acrylic lenses are soft and easy to fold and can be cost competitive. They remain common in Europe, Asia and value-oriented markets, though calcification risk must be controlled through material and manufacturing quality.
Silicone was an important early foldable material and remains in selected designs. Its flexibility supports small-incision implantation, but acrylic materials now dominate most new premium platforms.
Special polymers and adjustable materials serve niche products such as light-adjustable lenses and novel optical systems.
Pre-loaded IOLs are gaining the strongest share because they reduce handling steps and standardize delivery through increasingly small incisions.
The lens is supplied inside a sterile injector cartridge, reducing preparation and the risk of touching or damaging the optic. Bausch + Lomb's 2026 EyeGility launch illustrates the continued shift toward this format.
Surgeons or staff load the lens into a cartridge before implantation. This preserves flexibility across lens and injector combinations but adds handling steps.
Modern injector systems are engineered to deliver foldable lenses through micro-incisions with controlled unfolding, supporting increasingly standardized refractive cataract workflows.
North America is the largest regional market. The United States was approximately USD 1.7 billion in 2024 and combines high cataract surgery volume with strong uptake of toric, EDOF, multifocal and enhanced-monofocal lenses. FDA approval of TECNIS PureSee and the 2026 U.S. launch of Alcon Clareon TruPlus reinforce the region's role as an early premium-technology market.
Europe is a mature cataract-surgery region with strong premium adoption in private care and broad standard-lens coverage in public systems. Germany, France, the United Kingdom, Italy and Spain are major national markets, while EU MDR requirements influence product registration and lifecycle management.
Asia-Pacific is the fastest-growing region because of very large cataract burden, expanding surgery access and growing middle-class demand for premium visual outcomes. China, India and Japan are the largest opportunities, with India also serving as an important low-cost IOL manufacturing base.
Brazil and Mexico lead regional demand through public blindness-prevention programs and private refractive cataract services. Premium adoption is concentrated in urban private hospitals and ophthalmology centers.
GCC countries have advanced private ophthalmology and relatively high premium-IOL use, while much of Africa remains focused on reducing cataract backlog with affordable monofocal foldable lenses and high-volume surgical programs.
Foldable IOLs are implanted Class III devices in the United States and sit within a reimbursement environment that distinguishes medically necessary cataract treatment from optional refractive upgrades.
| Regulatory / Access Element | Current Position | Market Effect |
|---|---|---|
| FDA Class III / PMA | Intraocular lenses under product code HQL and related premium codes are Class III devices under 21 CFR 886.3600. | Raises evidence, manufacturing and lifecycle-management requirements. |
| TECNIS PMA lifecycle | FDA approved multiple manufacturing and sterilization supplements for TECNIS Foldable Acrylic IOLs during 2025–2026. | Demonstrates ongoing post-approval process control. |
| Premium reimbursement | Basic monofocal IOLs are more commonly covered than presbyopia-correcting upgrades. | Keeps patient out-of-pocket payment central to premium adoption. |
| Cataract surgery access | WHO reports that nearly half of people facing cataract blindness still need surgery. | Creates a major unmet-volume opportunity in low- and middle-income countries. |
| Patient selection | Multifocal and EDOF lenses require counseling on visual range, halos, glare and residual refractive error. | Makes surgeon recommendation and diagnostic work-up critical to conversion. |
Competition is led by global ophthalmic manufacturers with broad cataract-surgery ecosystems, while regional companies increase access in cost-sensitive markets.
Alcon's Clareon platform spans monofocal, toric, Vivity EDOF, PanOptix trifocal and the 2026 TruPlus enhanced-monofocal line, giving the company coverage across standard and premium segments.
The TECNIS portfolio includes monofocal, toric, multifocal and EDOF designs. TECNIS PureSee received U.S. approval in March 2026 and expanded U.S. availability in June.
The enVista platform spans standard and premium IOL options. The July 2026 EyeGility preloaded inserter launch strengthens delivery-system workflow around the enVista family.
ZEISS combines biometry, cataract workflow technology and premium IOL platforms, enabling integrated planning and implantation across refractive cataract surgery.
Regional manufacturers expand access through lower-cost monofocal and premium lenses and are especially important in India, China and other high-volume cataract markets.
16 July 2026: Bausch + Lomb launched the EyeGility preloaded IOL delivery system in the United States for the enVista family, initially for enVista Aspire and with enVista Envy availability planned afterward.
11 June 2026: Johnson & Johnson expanded U.S. availability of TECNIS PureSee, reporting that more than half a million eyes worldwide had already received the EDOF lens.
10 April 2026: Johnson & Johnson presented additional TECNIS PureSee clinical data at ASCRS 2026 following its U.S. approval, highlighting distance/intermediate vision and low rates of bothersome visual symptoms.
6 April 2026: Alcon launched Clareon TruPlus enhanced-design monofocal and toric IOLs in the United States at ASCRS 2026.
12 March 2026: Johnson & Johnson announced U.S. FDA approval of TECNIS PureSee, an EDOF intraocular lens intended for cataract surgery.
The global Foldable Intraocular Lenses (IOLs) market is projected to grow from USD 5.10 billion in 2026 to USD 8.23 billion by 2034, at a 6.2% CAGR. Growth will be supported by cataract surgery access, aging demographics, premium IOL adoption, preloaded delivery and rapid procedure expansion in Asia-Pacific.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Cataract treatment access | WHO identifies a large global surgery gap. | Supports strong unit growth. |
| Premium IOL mix | EDOF, toric and enhanced-monofocal options are expanding. | Raises average selling value. |
| Preloaded injectors | Manufacturers are simplifying lens delivery. | Improves workflow and premiumization. |
| North American innovation | 2026 product launches expand premium choices. | Sustains high-value regional demand. |
| Asia-Pacific surgery volume | China and India continue expanding cataract capacity. | Creates strongest incremental unit growth. |
The study supports cataract-device strategy, product portfolio planning, premium-IOL commercialization, hospital procurement and competitive benchmarking.
Market sizing combines bottom-up product, supplier, procedure or prescription, and pricing analysis with top-down demand validation. Quantitative inputs include patient or procedure volumes, product mix, replacement or prescription cycles, end-user structure, regional access, pricing and adoption of newer technologies.
Primary research validates purchasing or prescribing criteria, clinical workflow, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional bodies, peer-reviewed literature and official manufacturer information. Forecast assumptions are cross-checked against demographics, treatment access, regulatory activity, product launches and regional healthcare capacity.
Forecasts incorporate cataract surgery volumes, monofocal-versus-premium mix, material adoption, preloaded delivery penetration, average selling prices, refractive lens exchange, reimbursement and regional surgical access. North America remains the largest value market, while Asia-Pacific receives the strongest procedure-volume growth assumptions.
The market was valued at USD 4.80 billion in 2025 and is estimated at USD 5.10 billion in 2026. It is projected to reach USD 8.23 billion by 2034, representing a 6.2% CAGR.
Monofocal IOLs remain the largest type because of high cataract-surgery volume, predictable outcomes and lower cost than premium presbyopia-correcting lenses.
Hydrophobic acrylic is the leading material because of optical stability, controlled unfolding and broad use across standard, toric and premium lenses.
North America is the largest regional market, while Asia-Pacific is the fastest-growing major region.
Preloaded systems reduce manual lens handling, simplify surgical preparation and support reproducible delivery through small incisions.
FDA classifies intraocular lenses under 21 CFR 886.3600 as Class III implanted devices that require premarket approval.
The report profiles Alcon, Bausch + Lomb, ZEISS, Johnson & Johnson Surgical Vision, HOYA, OPHTEC, STAAR Surgical, Lenstec, HumanOptics, Biotech Healthcare, Omni Lens, EyeOL UK, Eyebright Medical Technology, Wuxi Vision Pro, Haohai Biological Technology and Aurolab.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
